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Inactivation of the p53 pathway represents the most common
molecular defect of human cancer. But in the setting of melanoma,
a highly aggressive and invariably fatal malignancy in its advanced
disseminated form, mutation/deletion of p53 is relatively rare,
whereas its positive regulator ARF is often lost. Here, we show that
genetic deficiency in Arf but not p53 facilitates rapid development
of melanoma in a genetically engineered mouse model. This
difference is accounted for, at least in part, by the unanticipated
observation that, unlike fibroblasts, senescence control in mela-
nocytes is strongly regulated by Arf and not p53. Moreover,
oncogenic NRAS collaborates with deficiency in Arf, but not p53, to
fully transform melanocytes. Our data demonstrate that ARF and
p53, although linked in a common pathway, suppress tumorigen-
esis through distinct, lineage-dependent mechanisms and suggest
that ARF helps restrict melanoma progression by executing the
oncogene-induced senescence program in benign nevi. Thus, ther-
apeutics designed to restore wild-type p53 function may be insuf-
ficient to counter melanoma and other malignancies in which ARF
holds p53-independent tumor suppressor activity.
genetically engineered mice  MET  nevi  p16INK4A  rhabdomyosarcoma
Cutaneous malignant melanoma is an extremely aggressive,often fatal disease that has proven to be largely resistant to
current therapeutic approaches. Melanoma incidence has in-
creased steadily for several decades, underscoring the need to
understand the genetic and environmental mechanisms driving
disease risk, initiation, and progression. Although significant
progress in our understanding of the etiologies and genetic
underpinnings of melanoma has recently been made (1), this
knowledge has yet to be translated into effective treatment
strategies. The INK4A-ARF (CDKN2A) locus on chromosome
9p21, often deleted or otherwise inactivated in heritable and
sporadic melanoma, is strongly implicated in melanoma sup-
pression (1). INK4A-ARF encodes two distinct tumor suppres-
sors, transcriptionally initiated from separate promoters and
read in two different reading frames: p16INK4A, referred to
hereafter as INK4A, and p14ARF (p19Arf in mouse), referred to
hereafter as ARF. INK4A positively regulates the pRB tumor
suppressor by inhibiting CDK4, and numerous studies have
documented inactivation of INK4A in human melanoma, often
sparing ARF (1). But the relevance of loss of ARF function as
a distinct event in melanoma has been demonstrated by reports
of ARF-specific, INK4A-independent mutations and ARF-
specific promoter methylation (1). In contrast, mutation of TP53
is infrequent in primary human melanoma (2), and, when TP53
mutations do occur, the mutant p53 tends to retain transacti-
vation function (3). ARF had been thought to function predom-
inantly as a positive regulator of the p53 tumor suppressor
through inhibition of MDM2 (4). However, experimental evi-
dence has recently emerged, mostly through an analysis of
fibroblasts, demonstrating roles for ARF distinct from its ability
to regulate p53 stability. Accordingly, ARF- and p53-deficient
mice do not exhibit identical tumor phenotypes, and ARF
interacts with a variety of other proteins, including E2F1, Myc,
NFB, and CtBP, and can function independently of p53 in
ribosome biosynthesis, DNA-damage response, apoptosis, and
autophagy (4).
Previous studies have shown that the INK4A/RB pathway plays
a significant role in human and mouse melanocyte senescence
(5–7). Here, we show that, in addition to INK4A, ARF strongly
regulates melanocyte proliferation, underscoring the detrimental
impact of loss of the INK4A-ARF locus so characteristic of human
melanoma (1). Moreover, we demonstrate that ARF, and not p53,
efficiently suppresses early melanoma genesis and operates inde-
pendently of p53 to induce senescence in melanocytes. This func-
tional distinction provides a mechanistic explanation for the com-
mon inactivation of ARF but only rare disruption of p53 in
melanoma.
Results and Discussion
The genetic and molecular pliability of the mouse make it an
exceptional model system to dissect the complex genetic principles
of human cancer. Previously, we demonstrated that transgenicmice
expressing the Met ligand hepatocyte growth factor/scatter factor
(HGF/SF) from the metallothionein promoter were prone to both
embryonal rhabdomyosarcoma (RMS) andUV-induced cutaneous
malignant melanoma that developed in stages highly reminiscent of
their human counterparts (8, 9). The risk of developing these two
malignancies was significantly enhanced when HGF/SF-transgenic
mice were placed on a genetic background in which the Ink4a-Arf
locus was genetically inactivated (10, 11). To elaborate the specific
roles of these tumor suppressors in oncogenesis, the HGF/SF
transgene was bred onto a background deficient in either Arf or
Ink4a alone. After neonatal UV irradiation, HGF/SF-transgenic
mice devoid of either Arf or Ink4a exhibited premalignant mela-
nocytic lesions by as early as 2 months of age and developed
cutaneous melanoma with a significantly reduced mean onset age
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of 3.5 months and 7 months, respectively (Fig. 1 a and b). The
mean onset age for melanoma in HGF/SF-transgenic Ink4a/
mice fell between the values for the Ink4a/ and Ink4a/ mice,
and the survival of the heterozygotes was significantly reduced
relative to Ink4a/mice. Somewhat unexpectedly, the mean onset
age for HGF/SF-transgenic Arf/ mice was not significantly dif-
ferent from Arf/ controls (Fig. 1a). Our mouse model therefore
readily confirmed the importance of these tumor suppressors in
melanoma (12, 13).
RMS was very common in HGF/SF-transgenic Arf/ mice,
irrespective of UV irradiation, with a mean age of onset of 3.7
months (Fig. 1c), and, again, the loss of one Arf allele did not
significantly affect RMS genesis. RMS was relatively rare in HGF/
SF-transgenic Ink4a/mice (Fig. 1d), suggesting that the Arf-p53
axis plays a critical role in suppression of embryonal RMS. Indeed,
this hypothesis was confirmed by generating HGF/SF p53 mutant
cohorts, showing that Tp53/ and Tp53/mice rapidly developed
RMS (Fig. 1e). Additionally, 14 of 14 RMS tumors arising in
Tp53/ mice sustained loss of the wild-type Tp53 locus (data not
shown). Nonetheless, the Rb pathway was typically disrupted in
RMS arising in Tp53/ mice, through either decreased pRb or
Ink4a expression or overexpression of Cdk4 or Cdk6 (data not
shown). These results suggest that, although p53 pathway disruption
is a preferential, critical early step in RMS genesis, Rb pathway
disruption still plays an important role later in progression.
Remarkably, HGF/SF-transgenic mice in which either one or
both Tp53 alleles were inactivated failed to develop melanocytic
lesions of any kind, while succumbing to RMS by a mean age of
onset of 2.7 or 1.4 months, respectively (summarized in Fig. 1f ).
This was in clear contrast to HGF/SF-transgenic mice deficient
in Arf, which experienced the same risk of developing either
melanoma or RMS with a mean onset age of 3.6 months (Fig.
1 a and c). The age at which the Arf-deficient mice developed
melanoma overlapped with the life expectancy of the Tp53/
mice: for example, one Arf/ mouse died at 72 days bearing a
melanoma of 120 mm3 as its only tumor. Based on the fact that
melanoma developed in p53-deficient mice expressing mutant
HRAS with a mean age of onset of 6 months (14; L. Chin and
N. Bardeesy, personal communication), it is very likely that
melanomas would have eventually developed in the HGF/SF-
transgenic p53-deficient mice had they not succumbed to RMS,
but at an age much later than the Arf-deficient mice. To
overcome the short lifespan of our p53-deficient cohorts, we
crossed the HGF/SF transgene onto a C57BL/6 background,
which resulted in more viable and long-lived transgenic mice
(HGF/SF-BL6); p53-deficient HGF/SF-BL6 mice live 50%
longer than their FVB/N counterparts. Of six such p53-deficient
HGF/SF-BL6 mice living an average age of 113 days, only one
(16.7%) developed a small 2-mm3 melanoma, and no melano-
cytic lesions developed in the only available HGF/SF-BL6
Tp53/ mouse, which lived 129 days. Similarly, 15% of HGF/
SF-BL6 mice with wild-type p53 developed melanoma at 113
days (n  24). Together, these data emphasize the relative
importance of Arf in melanocytes and raise the intriguing
possibility that Arf possesses melanoma tumor suppressor ac-
tivity that is independent of p53. This notion is supported by our
earlier work showing that melanomas in the UV-irradiated
HGF/SF-transgenic mouse often experience loss of exon 2 of the
Ink4a-Arf locus, but rarely harbored Tp53 mutations (11).
What ARF function then is critical for the suppression of
melanoma? An important process in which both RB and p53
pathways have been implicated is cellular senescence, thought to
constitute a physiological response to a variety of stressors long
evident in cultured cells (15, 16). Replicative senescence is triggered
by telomere exhaustion; however, senescence can be prematurely
induced by the expression of oncogenes such as mutant BRAF and
NRAS (17), commonly found in human nevi and melanoma (1). It
is now well appreciated that senescence represents a potent anti-
cancer mechanism, although the genetic wiring of the response
appears to be context dependent (17). In benign nevi, which consist
of senescentmelanocytes, oncogene-induced senescence represents
a critical block of progression to melanoma (5, 17, 18). INK4A has
been implicated in melanocyte senescence (5–7); however, recent
evidence suggests that INK4A alone may not be sufficient, and
another collaborating factor or factors may be required to execute
the melanocyte senescence program (17, 18).
We identified a senescent subset of lesional cells in early mela-
nomas arising fromourUV-irradiatedHGF/SF-transgenicmice, as
evidenced by positive staining with senescence-associated acidic
-galactosidase (SA--gal) (Fig. 2a). Based on our in vivo data, we
hypothesized that, unlike senescence in the well studied fibroblast
model systemArf, but not p53, may play a key role in the regulation
of melanocyte senescence. To test this notion, primarymelanocytes
were isolated from the neonatal skin of mice deficient in Arf, p53,
or Ink4a. Fig. 2b shows that, although wild-type melanocytes
senesced stably at 4 weeks, cultured primary Arf/ melanocytes
showed no detectable growth arrest over 3 months. Cultured
Fig. 1. Consequences of the loss of Arf, Ink4a, and p53 on development of
melanoma and RMS in HGF/SF-transgenic mice. (a) Melanoma Kaplan–Meier
(K–M) survival analysis of UV-irradiated Arf-deficient mice. Key is below the
figure: HGF/SF-transgenic (HGFtg), nontransgenic (Non-tg), tumor suppressor
(TS), wild type (/), heterozygote (/), or homozygote (/). Differences
between Arf homozygote and heterozygote, and Arf homozygote and wild
type were statistically significant (P  0.0053 and P  0.0001, respectively;
Tarone–Ware). (b) Melanoma K–M survival analysis of UV-irradiated Ink4a-
deficient mice. Differences between Ink4a wild type and heterozygote, and
Ink4a wild type and homozygote were statistically significant (P  0.023 and
P  0.0006, respectively; Tarone–Ware). (c) RMS K–M survival analysis of
Arf-deficient mice. (d) RMS K–M survival analysis of Ink4a-deficient mice. (e)
RMS K–M survival analysis of p53-deficient mice. ( f) Lifetime incidence of RMS
and melanoma in HGF/SF-transgenic mouse population with loss of various
tumor suppressors. Number (N) of mice in each group is below the graph.
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Ink4a/ melanocytes could also grow without signs of senescing
but required the presence of survival factors such as endothelin-1
and stem cell factor [supporting information (SI) Fig. 6a]. In
contrast, Tp53/ melanocytes on the same genetic background
initially exhibited slowed proliferation and the large size, hyperpig-
mentation, and positive SA--gal staining indicative of the senes-
cence observed in wild-type melanocytes (Fig. 2c and SI Fig. 6b).
After 50 days in culture, some p53-deficient melanocytes began
to recover, eventually growing at a rate similar to that of Arf-null
melanocytes (Fig. 2b). Notably, successful establishment of a
Tp53/melanocyte cell line (melan-p53–1) coincided initially with
full suppression of Ink4a expression (SI Fig. 7a). Subsequently, in
later passages, melan-p53–1 exhibited enhanced growth associated
with diminished expression of Arf (SI Fig. 7 b and c). These data
substantiate the idea that loss of p53 was insufficient to permit
melanocytes to escape senescence. Additional support for a re-
duced role for p53 in senescence inmousemelanocytes comes from
mice designed to express a hyperactive form of p53, which exhibit
accelerated cellular aging in various tissues but normal pigmenta-
tion of hair and skin (19). In human melanocytes, p53 appears to
contribute only subtly to replicative senescence (7, 20), suggesting
that the senescence molecular wiring may not be very different
between mouse and human melanocytes.
Cultures of early passage mouse melanocytes were then used to
study p53-independent Arf activity in melanocytes. To avoid the
rapid senescence that characterizes culturedwild-typemelanocytes,
subsequent experiments were performed with melanocytes whose
growth was enabled by germ-line deficiency of Ink4a. This is a
relevant genetic context for studying the consequences of Arf
deficiency because, in human melanoma genesis, ARF is frequently
lost in conjunction with loss of INK4A. Expression of p53 was
knocked down in the presence and absence of Arf by using a
retroviral vector containing a p53-specific shRNA-mir (LUMP-
p53.1224) (21). This retroviral vector efficiently knocked down p53
RNA and protein levels (Fig. 3 a and b) and blocked its ability to
induce p21 expression after -irradiation (Fig. 3b). The following
melanocyte lines were used: Ink4a/, Ink4a-Arf/, Ink4a/ with
p53 knockdown, and Ink4a-Arf/ with p53 knockdown. Growth
analysis of these four cell lines in vitro showed that melanocytes
deficient in Arf exhibited a strong growth advantage relative to
those carrying wild-type Arf, a phenotypic difference not overtly
affected by the functional status of p53 (Fig. 3c). This result was
confirmed in melanocyte line melan-p53–1, derived from Tp53/
mice (SI Fig. 7c). These data indicate that Arf regulatesmelanocyte
proliferation in a p53-independent manner.
To further evaluate the role of Arf in melanocyte senescence, a
retroviral vector was used to restore expression of Arf in Ink4a-
Arf/ melanocytes, with and without p53 knockdown (Fig. 3a).
Forty-eight hours after infection, Arf expression inhibited cell
proliferation (Fig. 3d) and induced morphological senescence as
evidenced by SA--gal staining, irrespective of the presence of
functional p53 (Fig. 3e). This result was confirmed in Arf-infected
melan-p53–1 melanocytes (SI Fig. 8a). Moreover, the ability of Arf
to induce senescence in this Tp53/ cell line was corroborated
through analysis of phosphorylation of heterochromatin protein-1
(HP1) (Fig. 3f) and its association with prominent senescence-
associated heterochromatin foci (SI Fig. 8b) (22). In contrast, Arf
reexpression in Ink4a-Arf/ melanocytes did not induce an overt
apoptotic response over this time period, irrespective of p53
expression (SI Fig. 9a).
To determine possible targets of p53-independent Arf control
over melanocyte cell proliferation, luciferase reporter assays
were used. Although found to be a target of Arf regulation in
other cell types (4), Myc activity was not significantly affected by
the loss of Arf in melanocytes (Fig. 4b). E2F1 has also been
reported to be a direct, p53-independent target of ARF (4, 23).
We discovered that E2F activity was significantly elevated in
melanocytes devoid of Arf (Fig. 4a). Knockdown of p53 had no
overt effect on E2F activity by itself but did enhance the activity
achieved through loss of Arf alone, although this change did not
reach significance. Subsequent analysis revealed that levels of
E2F1 were greatly enhanced in Arf-deficient melanocytes rela-
tive to wild type (Fig. 4c). The consequence of p53 loss mirrored
the luciferase reporter assay in that no effect was observed unless
Arf expression was also lost (Fig. 4c). To further investigate the
mechanism of Arf-regulated E2F1 expression, Arf was reex-
pressed in Arf-deficient melanocytes in the presence and ab-
sence of a proteasomal inhibitor. Arf reexpression decreased the
level of E2F1; however, this effect was abrogated in the presence
of the proteasomal inhibitor, LLnL (Fig. 4d). These data dem-
onstrate that Arf down-regulates melanocyte E2F1 levels
through a proteasomal-degradation mechanism that could ac-
count, at least in part, for its ability to trigger melanocyte growth
arrest. Importantly, E2F activity has been associated with se-
nescence in mouse and human melanocytes and has been
implicated in human melanoma (24–26). However, because Arf
has many binding partners and other activities (4), additional
mechanisms may be involved in Arf-mediated senescence.
Having demonstrated the importance of Arf in the regulation of
melanocyte senescence, we next determined whether Arf was a
barrier to melanocyte transformation by NRAS, frequently mu-
Fig. 2. Loss of Arf function bypasses senescence in primary mouse melano-
cytes. (a) SA--gal staining in an early cutaneous melanoma arising in a
UV-irradiated HGF/SF-transgenic mouse. (Inset) Higher magnification of blue-
stained cells. (b) Growth analyses of primary mouse melanocytes isolated and
cultured from wild-type, Arf-deficient, and p53-deficient neonatal mouse
skins. Each curve represents a separate primary line from one mouse. For each
data point (i.e., each passage), melanocytes were collected from triplicate
3-cm dishes by trypsinization, each suspension was counted in triplicate, and
cells were replated at 3  104 cells per ml. The mean relative population
increase was calculated and converted to number of population doublings.
SEMs are no bigger than the symbols, and no more than 7% of the mean. (c)
Microscopic image of melanocytes by using phase contrast (Upper) and bright
field microscopy after staining for SA--gal (Lower). Blue indicates senescent
cells; stain is masked by melanin in some cells.
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tated in humanmelanoma (1).We again used the set of four mouse
melanocyte lines growth-enabled through deficiency of Ink4a; all
cells were subjected to infection by a retrovirus encoding mutant
NRAS. Enhanced expression of NRASwas confirmed by RT-PCR
(Fig. 5a). We found that, in the context of NRAS activation (and
Ink4a-deficiency), loss of Arf, but not p53, was sufficient to confer
both a transformed morphology (Fig. 5b) and the capability for
anchorage-independent growth (Fig. 5c and SI Fig. 9b). This result
was confirmed in melan-p53–1 melanocytes, which were not trans-
formed by NRAS (SI Fig. 8c). The role of Arf in melanocyte
Fig. 3. Proliferation of mouse melanocytes is regu-
lated by Arf but not p53. (a) To avoid studying senes-
cence-prone melanocytes, all cells were genetically
Ink4a-deficient. p53 expression was stably knocked
down (KD) in Ink4a/ and Ink4a-Arf/ (KO) melano-
cytes by infection with retrovirus LUMP-p53.1224, a
shRNA-mir (21). Arf was reexpressed in Ink4a-Arf/
melanocytes by infection with a pBabe retrovirus con-
taining Arf cDNA () (23). Melanocytes are wild type
for a given allele unless otherwise indicated. Expres-
sion of Arf (top blot) and p53 (middle blot) RNA was
assessed by RT-PCR; GAPDH RNA expression was used
as control (bottom blot). (b) p53 activity was blocked
by expression of the shRNA-mir. Ink4a/, Ink4a/
with p53KD, Ink4a-Arf/, and Ink4a-Arf/ with
p53KD melanocytes were treated with either 0 or 1M
ADR (upper set of blots), or 0 or 20 Gy -IR (lower set
of blots). Expression of p53 and p21 was detected by
immunoblotting and -actin antibody used to confirm
equal loading. (c) Growth analysis of established
p53KD melanocytes. Ink4a/, Ink4a/ with p53KD,
Ink4a-Arf/, and Ink4a-Arf/ with p53KD melano-
cytes were seeded at 1  105 cells per dish, and cell
numbers were counted between 2 and 10 days. Data
points represent means  SE of three independent
experiments. Growth of all cells expressing Arf was
significantly different from cells without Arf (P 
0.001). (d) Ink4a-Arf/ and Ink4a-Arf/ with p53KD
melanocytes were infected with the pBabe retrovirus
containing Arf cDNA or empty vector, as shown in a,
and the number of cells were counted at 24 and 48 h
after infection. (e) Cells were stained with SA--gal at
48 h after retrovirus infection. Blue indicates senescent
cells, as in 2c. ( f) Overexpression of Arf induces phos-
phorylated HP1. The Tp53/melanocyte line melan-
p53–1 was infected with pBabe retrovirus containing
Arf cDNA or empty vector. Forty-eight hours after
infection, HP1was analyzed by immunoblotting (22).
Total and phosphorylated HP1 are indicated, as are
Arf and a -actin loading control.
Fig. 4. E2F1 level and activity are significantly en-
hanced upon inactivation of Arf. (a) Ink4a/, Ink4a/
with p53KD, Ink4a-Arf/, and Ink4a-Arf/ with
p53KD melanocytes were transfected with a luciferase
reporter plasmid for E2F activity (E2F-luc). Luciferase
activity, normalized to readings from a cotransfected
pRL-TK plasmid, was measured after 16 h. Data repre-
sent means SE of three independent experiments of
three replicates each. Asterisks indicate a statistically
significant difference between samples (P  0.05). (b)
Same as a, but here, a reporter for Myc activity was
used (Myc-luc). (c) Western blot showing expression of
E2F1 in Ink4a/, Ink4a/ with p53KD, Ink4a-Arf/,
and Ink4a-Arf/ with p53KD melanocytes (upper
blot). -Actin was used as control for protein loading
(lower blot). (d) Arf can induce E2F1 degradation. Arf
was reexpressed in Ink4a-Arf/melanocytes by infec-
tion with a retrovirus containing Arf cDNA. Melano-
cytes were treated with proteasomal inhibitor 50 M
LLnL or vehicle for 16 h at 24 h after infection. Western
blots depict expression of E2F1 (top blot), Arf (middle
blot), and -actin as loading control (bottom blot).
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transformation was further characterized by in vivo growth analysis
in nude mice. The results showed that, in concert with mutant
NRAS, the loss of Arf, but not p53 alone, allowed melanocytes to
form tumors readily in vivo (Fig. 5d). Interestingly, we did note an
effect of p53 loss with respect to E2F activity, soft agar growth, and
tumorigenesis, but only in melanocytes already deficient in Arf,
reinforcing the concept that Arf and p53 possess discrete functions
in melanocytes and melanoma. These data corroborate our initial
findings in the transgenic mouse model and support a prominent,
distinct role for ARF and a muted or delayed role for p53 in
suppressing melanoma.
Melanocytes are highly specialized cells built to absorb and
survive significant stress associated with melanin production and
UV exposure and can be intermittently induced into temporary
states of active proliferation. Here, we show that, unlike fibro-
blasts, where p53 inactivation is sufficient to prevent fibroblast
senescence and ARF expression can only trigger fibroblast
growth arrest and senescence in the presence of functional p53
(15, 27–30), Arf can regulate melanocyte senescence in a manner
independent of p53 and distinct from Ink4a. Loss of Arf in
melanocytes results in a significant growth advantage relative to
p53 or Ink4a deficiency, whereas restoration of Arf induces
cellular growth arrest, senescent morphological alterations, SA-
-gal expression, and phosphorylation of HP1, irrespective of
p53 status. Moreover, data derived from transgenic mice and
NRAS-transformed melanocytes validate the relevance in mel-
anoma genesis of loss of ARF vis-a`-vis p53.
If indeed the molecular wiring of senescence is sufficiently
similar in mouse and human, then the ability of ARF to regulate
melanocyte senescence and influence melanoma genesis in a
p53-independent manner has clinical significance. Deletions at
the CDKN2A locus are currently the second most frequent
genetic event in cancer, second only to TP53 alterations. ARF/
p53 pathway members would seem then to comprise very
promising candidates for broadly effective targeted therapy.
Development of novel, rational therapies based on p53 is ongo-
ing and has focused mainly on targeting MDM2/p53 interactions
and the use of small molecules to alter the conformation of
mutant p53 to restore wild-type function and not on ARF (31).
However, our data demonstrate that the function of ARF and
p53 in melanocytes and their roles in melanoma are not redun-
dant. Saadatmandi et al. (32) showed that ARF expression can
suppress the growth and viability of a variety of human tumor
cells both with and without functional p53. In the future, it may
be prudent to determine the presence and influence of alter-
ations in ARF separately from those in p53 for individual
melanoma cases and stratify patients for treatment accordingly.
Materials and Methods
Details of some materials and methods are available in the SI
Text.
Genetically Engineered Mice. Mice carrying a HGF/SF transgene
whose expression is regulated by a metallothionein gene promoter
and flanking regions were made as described (8). Mice carrying
specific inactivating mutations in Arf or Ink4a were generated as
described (33). Tp53/mice (34) were obtained fromThe Jackson
Laboratories (Bar Harbor, ME). Unless otherwise indicated, all
mice were on a genetic background consisting of 90% FVB/
N:10% C57BL/6. All melanomas were initiated by a single dose of
UV radiation at 3.5 days of age as described (9). RMS development
was unaffected by UV irradiation, so UV irradiated and untreated
cohorts were combined. Primers used for genotyping are listed in
SI Table 1. All mouse work was performed with the approval of the
National Cancer Institute Animal Care and Use Committee, in
accordance with American Association for the Accreditation of
Laboratory Animal Care guidelines and policies established by the
National Institutes of Health.
Melanocyte Derivation, Culture, and Growth Curves. All melano-
cytes were derived from mouse stocks on a C57BL/6J back-
ground, including: Arf/ mice [a gift from F. Zindy and C.
Sherr (St. Jude Children’s Research Hospital)], Ink4a/ mice
(Ink4a*/*) (12) and Tp53/ mice (34) (The Jackson Labora-
tories). Primary melanocyte cultures were prepared from
neonatal skins as described by using a feeder layer of mito-
mycin-treated immortal murine XB2 keratinocytes for the first
two passages only (35). Cultures were grown at 37°C in RPMI
medium 1640 with 10% FBS, 200 nM 12-O-tetradecanoyl
phorbol 13-acetate, and 200 pM cholera toxin (35), hereafter
referred to as complete melanocyte growth medium (CMGM).
They were gassed with 10% CO2 in humidified air, final pH
6.9–7.0. Ink4a-deficient cultures were additionally supple-
mented with 10 ng/ml recombinant mouse stem cell factor
(SCF; R & D Systems, Minneapolis, MN) and 10 nM endo-
thelin-1 (Sigma–Aldrich, St. Louis, MO). Medium was
changed twice weekly.
Long-term growth curves were generated from several inde-
pendent primary lines (each from one skin) per genotype.
Number of lines generated: three for Tp53/, two for Arf/,
four for Ink4a/, and eight for wild-type melanocytes. Cells
were collected from triplicate 3-cm dishes per line by trypsiniza-
tion and each suspension counted in triplicate by hemocytometer
Fig. 5. NRAS collaborates with Arf deficiency to transform melanocytes. (a)
Ink4a/, Ink4a/ with p53KD, Ink4a-Arf/, and Ink4a-Arf/ with p53KD
melanocytes were infected with vector LZRS containing mutant NRAS (G12V)
(36). RT-PCR demonstrated NRAS expression levels with and without infection
(upper blot). GAPDH served as a control (lower blot). (b) Microscopic image of
the phenotypic consequences of mutant NRAS expression in melanocytes. All
images show NRAS-infected cells. (c) Quantification of the ability of melano-
cytes to grow under anchorage-independent conditions after NRAS infection
(in colonies per well). All experiments were in triplicate; bars represent
mean SE of three wells. P 0.057 for Ink4a/Arf/with and without p53KD.
(d) In vivo tumor growth analysis of NRAS-transformed melanocytes. NRAS-
transformed melanocytes were collected and s.c. inoculated at 0.5 106 cells
per injection site per nude mouse. Tumor volume was measured every 3 days
after injection. Data points represent mean tumor volumeSE (error bars for
some points are too small to see); five mice in each group.
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and replated at 3  104 cells per ml, 2 ml per dish. The mean
relative population increase was calculated and converted to
number of population doublings.
For other experiments, melanocytes were grown as above except
with 5% CO2, the pH being adjusted with HCl to reach pH 7.1–7.2
on incubation. Medium was replaced every 48 h. For short-term
growth curves, Ink4a/, Ink4a/ with p53 knockdown, Ink4a-
Arf/, Ink4a-Arf/ with p53 knockdown and melan-p53–1 mela-
nocytes were plated at 1  105 cells per 10-cm dish. Cells were
collected by trypsinization and counted by using a Coulter counter
(Beckman, Fullerton, CA) every 2 days. The experiment was
performed three times with triplicate dishes.
Adriamycin (ADR) (Sigma–Aldrich) was dissolved in deion-
ized H2O and sterilized by passage through a 0.2-m filter before
use. Cells were treated with a final concentration of 1 M ADR
for 4 h in CMGM. Twenty grays of -irradiation was used for p21
induction. Cells were incubated at 37°C for 1 h after irradiation.
LLnL (Sigma–Aldrich) was dissolved in 95% ethanol. Cells were
treated with a final concentration of 50 M LLnL for 16 h in
CMGM. Cells were rinsed with PBS and collected for analysis
after individual treatment.
Vectors and Generation of Modified Cell Lines.Melanocytes with p53
knockdownwere generated by infectionwith the retrovirus LUMP-
p53.1224, which contains a p53-specific shRNA-mir (21). Briefly,
EcoPack 293 cells were transfected with 10 g of DNA, and viral
supernatant was collected after 2 days and used to infect melano-
cytes. Cells were selected in 1.5g/ml puromycin. Expression ofArf
and NRAS in cultured melanocytes was carried out by infection
with the retrovirus pBabe containing Arf or the vector LZRS
containing NRAS (G12V) (36), respectively, by using the same
procedure. The Arf cDNA retrovirus was constructed as described
(23), and the pBabe vector was used as a control.
SA--Gal Staining. SA--gal staining was performed by using a
senescence-detection kit (Biovision Research Products, Mountain
View, CA) according to the manufacturer’s instructions. Briefly,
mouse melanocytes were fixed 48 h after infection with Arf
retrovirus or control and incubated overnight at 37°C with staining
solution. For tumor samples, fresh-frozen tissues were fixed in
formaldehyde/glutaraldehyde for 10 min at room temperature.
Slides were rinsed with PBS and incubated in staining solution [1
mg/ml -galactosidase, 40 mM citric acid/sodium phosphate (pH
6.0), 5 mM potassium ferrocyanide, 0.15 M sodium chloride, and 2
mMmagnesium chloride] at 31°C overnight. Slides were thoroughly
rinsed and counterstained with 0.1% neutral red. For primary
melanocytes, staining was performed between passages 3–5.
Statistical Analysis. The differences in growth in vitro and in vivo
among the four cell lines were tested by using the analysis of
covariance (ANCOVA). In the model, time was included as a
covariate to reflect cell proliferation or tumor growth. Analysis was
done by using SAS PROC GLM. For Kaplan–Meier survival
curves, the Tarone–Ware method was used, and for analysis of
luciferase activity, Student’s t test was used.
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